KPTI - Karyopharm -8% announces preliminary Q4 and FY numbers

Karyopharm Therapeutics ([[KPTI]] -8.0%) expects total Q4 revenues to be between $35M-36M and between $108M-109M for the FY of 2020, including net product sales for XPOVIO.Additionally, company expects net product sales of XPOVIO to be between $20M-20.5M during Q4 and between $76M- -76.5M for the FY 2020.Net sales for Q4 were largely driven by prescription demand from both academic and community-based oncologists for patients with penta-refractory multiple myeloma.Finally, ~$15M of license revenue was also recognized in the Q4 following progress made toward the international expansion for XPOVIO.XPOVIO sales in Q4 were ~4-6% lower than Q3.XPOVIO prescription demand was higher in December 2020 compared to either October or November 2020.Sales were affected by the recent surge in U.S. COVID-19 cases impacting both patient visits to their healthcare providers, as well as reduced in-person access for the company's commercial team to its physician customers."2020 was a pivotal year for Karyopharm as XPOVIO received two FDA

For further details see:

Karyopharm -8% announces preliminary Q4 and FY numbers